In a phase 3 trial published Oct. 23, 2026, in JAMA, women with HER2-low metastatic breast cancer went a median 16.4 months without progression on trastuzumab rezetecan vs. 6.8 months on chemotherapy, with more serious blood-related side effects.
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with endometrial cancer that progressed after chemotherapy and immunotherapy lived a median 19.0 months on sacituzumab tirumotecan, vs. 12.1 months on the doctor's choice of chemotherapy.
A network meta-analysis published Oct. 1, 2026, in JAMA Network Open linked risk-reducing mastectomy to lower all-cause mortality than MRI-based screening (hazard ratio 0.37) in women with BRCA1 or BRCA2 variants, though certainty was very low.
Five-year results of the PHERGain trial, published Oct. 29, 2026, in Nature Medicine, show that 89.5% of women on a PET-guided plan were free of invasive disease, and 92.4% of those who responded well without chemotherapy.
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with advanced mismatch repair-deficient endometrial cancer went a median 38.2 months without progression on pembrolizumab alone, vs. 8.4 months on chemotherapy, with fewer serious side effects.
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with HR+/HER2- breast cancer that had progressed after hormone therapy, CDK4/6 inhibitors and chemotherapy went a median 8.2 months without progression on iza-bren vs. 4.0 months on…
An ASCO living guideline published Oct. 27, 2026, in the Journal of Clinical Oncology says everyone with newly diagnosed advanced ovarian cancer should get genetic testing, and that PARP inhibitor maintenance should be prioritized after the first remission, not used…
In a phase 3 trial in China published Oct. 24, 2026, in NEJM, 58.5% of women with HER2-positive advanced breast cancer on anbenitamab plus a docetaxel formulation were free of progression at 24 months vs. 34.4% with the standard combination.